Dying, Fast and Slow: The Ethics of Living Longer | Raiany Romanni-Klein | TEDxBoston

Quick Overview

Raiany Romanni-Klein argues that humanity must shift its focus from treating individual age-related diseases one by one toward tackling the underlying biology of aging to maximize healthspan and economic returns, citing the massive economic benefit of extending healthy life, which is currently undervalued compared to spending on treating late-stage diseases.

Key Points: Historically, most deaths were 'fast deaths' (infection, accidents, etc.), but since the 20th century, the majority of deaths are now 'slow deaths' from age-related diseases, like cardiovascular disease (killing nearly 1/3 globally). In the US in 2025, average life expectancy is 79, but the average person receives their first chronic disease diagnosis around age 50, meaning about 29 years are spent in declining health. Addressing aging itself offers massive economic returns; curing all cancers, for example, is projected to yield $80T in economic value to the US over decades, far exceeding the current NIH funding for the biology of aging ($500M vs $18B for other late-stage diseases). The speaker proposes five potential solutions to slow death, including setting a maximum lifespan of 65 (which she deems unethical) and focusing on treating the diseases of aging one by one, noting that curing all cancers only adds about 2.5 years to life expectancy. She champions fundamental research into aging biology, showing that slowing aging by just one year could result in a $3T annual gain to the US GDP. The speaker points out that the current funding model for diseases like Alzheimer's is circular and based on urgency rather than impact, as research is funded because it's difficult and urgent, leading to a lack of focus on fundamental aging research. If humans lived as long as some other species (like the Greenland Shark at 500 years) or could extend their productivity years, the economic gains would be enormous, potentially adding trillions to the US GDP.

Context: Raiany Romanni-Klein, CEO of the Institute for Life and Technology, presents a TEDxBoston talk arguing for a paradigm shift in medical research funding from treating individual age-related diseases to targeting the underlying biological processes of aging. She uses historical data, economic projections, and biological examples (like the C. elegans worm and long-lived species) to illustrate the massive untapped economic and human potential of extending 'healthspan' rather than just treating terminal conditions.